Cash Flow Statement
Growth Metrics

Ani Pharmaceuticals (ANIP) Liabilities and Shareholders Equity (2016 - 2026)

Ani Pharmaceuticals' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $1.4 billion for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 12.14% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $5.5 billion, a 24.43% increase, with the full-year FY2025 number at $1.4 billion, up 12.14% from a year prior.
  • Liabilities and Shareholders Equity hit $1.4 billion in Q4 2025 for Ani Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for ANIP hit a ceiling of $1.4 billion in Q4 2025 and a floor of $463.8 million in Q1 2021.
  • Historically, Liabilities and Shareholders Equity has averaged $924.6 million across 5 years, with a median of $874.6 million in 2023.
  • The widest YoY moves for Liabilities and Shareholders Equity: up 67.31% in 2021, down 3.81% in 2021.
  • Tracing ANIP's Liabilities and Shareholders Equity over 5 years: stood at $771.6 million in 2021, then decreased by 1.49% to $760.1 million in 2022, then increased by 18.99% to $904.4 million in 2023, then skyrocketed by 42.02% to $1.3 billion in 2024, then rose by 12.14% to $1.4 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ANIP at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.3 billion in Q2 2025.